ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer — Stella

Home/Endometrial Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Endometrial Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Key details

Phase

Early testing

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

Genentech, Inc., Oncoceutics, Inc.

Enrollment target

~58 participants

Started

October 2023

Primary completion

February 2028

Age range

18 Years and older

Sex

Female only

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.